Updated:
BB Pureos Bioventures
Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and...
Overview
Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats. The firm strives to impact patients' lives by advancing innovative treatments for severe diseases. Its portfolio companies develop innovative therapeutics for severe diseases and conditions.
General information
Firm type
Venture Capital
Location
Region
Europe
Country
Switzerland
City
Zurich
Corporate office
Zurich, Switzerland
Principals
Dr. Dominik Escher
Managing Partner
Dr. Klaus Breiner
Managing Partner
Dr. Martin Münchbach
Managing Partner
Dr. Veronica Gambillara Fonck
Partner
Dr. Anne Grahl
Investment Manager
Dr. Butrint Aliu
Associate
Stefano Lamaro
Analyst
Oliver Fries
Head Finance & Operations
Deborah Thum
Sales Assistant & Office Manager
Dr. Dragan Grabulovski
Venture Partner
Dr. Lars Nieba
Venture Partner
Prof. Dr. Sai Reddy
Venture Partner
Prof. Dr. Thomas Baumert
Advisory Board
Dr. Omar Khwaja
MD PhD, Advisory Board
Prof. Dr. Roger Nitsch
Advisory Board
Dr. Sonia Quaratino
MD PhD, Advisory Board
Prof. Dr. Bernd Seizinger
Advisory Board
Dr. Mathieu Simon
Advisory Board
Ben Morgan
General Partner Board
Karen Haith
General Partner Board
Pascal Mahieux
General Partner Board
Sector focus
Frequently asked questions
What stages does BB Pureos Bioventures target?
The firm focuses on early stage, seed, and growth equity.
Where is BB Pureos Bioventures based?
Headquarters are in Zurich, Switzerland.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: